Published in Women's Health Weekly, June 27th, 2002
AstraZeneca filed the sNDA with the FDA for Arimidex on March 4, 2002, having received fast track designation in December of 2001, allowing a rolling submission. Priority review status is granted for new drugs or indications that represent a significant improvement in efficacy or safety over existing treatments.
"AstraZeneca is committed to constantly expanding the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.